Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 1.00 |
| ▸ | DRD1 | P21728 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 0.76 |
| ▸ | DRD4 | P21917 | 3/20 | 0.76 |
| ▸ | DRD5 | P21918 | 3/20 | 0.76 |
| ▸ | HRH1 | P35367 | 3/20 | 0.76 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Desmethylclozapine SCHEMBL29365906 | 1.00 | DRD2 (1.00) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| N-Desmethylclozapine SCHEMBL29360816 | 1.00 | DRD2 (1.00) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| N-Desmethylclozapine SCHEMBL30416482 | 1.00 | DRD2 (1.00) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| SCHEMBL3431059 | 0.95 | DRD2 (0.91) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| SCHEMBL20887469 | 0.92 | DRD2 (0.88) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| SCHEMBL3411298 | 0.91 | DRD2 (0.83) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| SCHEMBL3408005 | 0.90 | DRD2 (0.82) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| SCHEMBL3411946 | 0.90 | DRD2 (0.82) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| SCHEMBL3407780 | 0.90 | DRD2 (0.81) | DRD2DRD1CHRM1CYP1A2CHRM2 | |
| SCHEMBL3411880 | 0.89 | DRD2 (0.80) | DRD2DRD1CHRM1CYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230288372-A1 | Systems and Methods for Separating Compounds of Similar Mass by Differential Mobility Spectrometry | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2023-09-14 | — | — | US | claimed |
| EP-4100733-A1 | SYSTEMS AND METHODS FOR SEPARATING COMPOUNDS OF SIMILAR MASS BY DIFFERENTIAL MOBILITY SPECTROMETRY | DH Technologies Development Pte. Ltd. (SG) | 2022-12-14 | — | — | EP | claimed |
| WO-2021156775-A1 | SYSTEMS AND METHODS FOR SEPARATING COMPOUNDS OF SIMILAR MASS BY DIFFERENTIAL MOBILITY SPECTROMETRY | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2021-08-12 | — | — | WO | claimed |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-09-17 | — | — | US | claimed |
| EP-3432884-A1 | COMBINATION FOR TREATING PAIN | Regents of the University of Minnesota (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165558-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-09-28 | — | — | WO | claimed |
| EP-3137658-A1 | USE OF KNOWN COMPOUNDS AS D-AMINO ACID OXIDASE INHIBITORS | Tseng, Yufeng, Jane (US) | 2017-03-08 | — | — | EP | claimed |
| WO-2016023997-A1 | HETEROCYCLIC COMPOUNDS WITH WORKING MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2016-02-18 | — | — | WO | claimed |
| US-20150374712-A1 | Combinations of Dopamine D2 Receptor Blockade With Norepinephrine Reuptake Inhibition and with Norepinephrine Alpha 2 Receptor Blockade | GREEN ALAN I (US) | 2015-12-31 | — | — | US | claimed |
| WO-2012161938-A1 | CLOZAPINE IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2012-11-29 | — | — | WO | claimed |
| WO-2006001866-A2 | CRYSTALLINE FORMS OF N-DESMETHYLCLOZAPINE | ACADIA PHARMACEUTICALS INC. (US) | 2006-01-05 | — | — | WO | claimed |
| EP-1596867-A2 | TREATMENT OF PSYCHOSIS WITH A MUSCARINIC M1 RECEPTOR ECTOPIC ACTIVATOR | Merck & Co., Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| EP-1589974-A2 | USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE | Acadia Pharmaceuticals Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| EP-1587789-A2 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES | Acadia Pharmaceuticals Inc. (US) | 2005-10-26 | — | — | EP | claimed |
| WO-2005063254-A2 | AMINO SUBSTITUTED DIARYL[A,D]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS | ACADIA PHARMACEUTICALS INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | claimed |
| WO-2005018541-A2 | COX-2 INHIBITOR AND SEROTONIN MODULATOR FOR TREATING CNS DAMAGE | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2004073639-A2 | TREATMENT OF PSYCHOSIS WITH A MUSCARINIC M1 RECEPTOR ECTOPIC ACTIVATOR | MERCK & CO. INC. (US) | 2004-09-02 | — | — | WO | claimed |
| WO-2004064753-A2 | USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE | ACADIA PHARMACEUTICALS INC (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004064738-A2 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2004-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | DRD2 327/4885DRD1 1384/4885CHRM1 962/4885 |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | OPRL1, ACHE, OPRK1 | DRD2 1728/4885DRD1 3062/4885CHRM1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.